Adaptive Biotechnologies (ADPT) Operating Income (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Operating Income data on file, last reported at -$19.2 million in Q1 2026.

• Quarterly Operating Income rose 35.12% year-over-year to -$19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.7 million (up 67.41% YoY) and the FY2025 annual result came in at -$57.1 million, up 64.86% from the prior year.
• Operating Income slipped to -$19.2 million in Q1 2026 per ADPT's latest filing, from -$12.8 million in the prior quarter.
• The five-year high for Operating Income was $10.3 million in Q3 2025, with the low at -$71.1 million in Q4 2023.
• Average Operating Income over 5 years is -$39.2 million, with a median of -$45.4 million recorded in 2022.
• Year-over-year, Operating Income slumped 81.36% in 2023 and jumped 131.53% in 2025.
• Adaptive Biotechnologies' Operating Income stood at -$39.2 million in 2022, then tumbled by 81.36% to -$71.1 million in 2023, then surged by 52.39% to -$33.8 million in 2024, then surged by 62.25% to -$12.8 million in 2025, then plunged by 50.36% to -$19.2 million in 2026.
• Business Quant data shows ADPT's Operating Income at -$19.2 million in Q1 2026, -$12.8 million in Q4 2025, and $10.3 million in Q3 2025.